Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their written agreement to take part voluntarily
- People whose condition has been diagnosed according to the World Health Organization (WHO) 2008 classification guidelines
- People whose leukemia did not go into full remission after initial treatment, or who relapsed after remission, and where more than 5% of cells in the blood or bone marrow are leukemia cells
- People whose leukemia cells test positive for certain markers called CD7 or CD5 (at 70% or higher on lab testing)
- People whose doctors expect them to survive for more than 12 weeks
- People who are largely able to care for themselves and carry out daily activities (a medical scoring system called ECOG rates this as 2 or lower)
- People aged between 2 and 60 years old
- People whose haemoglobin (a measure of red blood cells) is at least 70 g/L, including if this level is reached through a blood transfusion
- People whose liver function test results are within acceptable ranges (bilirubin no more than 3 times the normal upper limit, and liver enzymes AST and ALT no more than 5 times the normal upper limit)
Who may not be able to join:
- People who do not wish to give consent for treatment
- People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
- People with certain heart conditions, including atrial fibrillation, a heart attack within the past 12 months, long QT syndrome or related conditions, significant fluid around the heart, or serious heart failure (rated as Class III or IV by medical standards)
- People with a history of serious lung disease affecting lung function
- People with a severe or ongoing infection that cannot be brought under control
- People with a serious autoimmune disease or a condition where the immune system does not work properly from birth
- People with active hepatitis (liver inflammation caused by a virus)
- People living with HIV (human immunodeficiency virus)
- People with significant active viral infections, or viral infections that have reactivated and cannot be controlled, including Epstein-Barr virus (EBV)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +12077706670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The number and incidence of adverse events after CD7/CD5 CAR infusion.; Disease response to CD7/CD5 CAR T cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.